BioPharmSignal logoBioPharmSignal

Biotech News

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics (GPCR)Structure TherapeuticsConference / presentation

Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail dose-dependent, clinically meaningful

Related news

GPCRStructure Therapeutics2026-09-08 12:00 EST

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

GPCRStructure Therapeutics2026-09-03 11:30 EST

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

VERAVera Therapeutics2026-10-02 13:24 EST

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

CMMBChemomab Therapeutics2026-08-31 12:00 EST

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

ACRSAclaris Therapeutics2026-09-03 12:00 EST

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

ELDNEledon Pharmaceuticals, Inc.2026-10-05 20:05 EST

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

ANABAnaptysBio, Inc.2026-09-01 20:15 EST

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

IMMPImmutep Limited2026-07-24 12:00 EST

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

View all latest news

Structure Therapeutics

Structure-Based Metabolic Drug Discovery Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies. Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity...

Recent company news

GPCRStructure Therapeutics2026-09-08 12:00 EST

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

GPCRStructure Therapeutics2026-09-03 11:30 EST

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-06-05 20:05 EST

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Stock data

Close
27.47 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States